With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
Sunway Biotech Co. Ltd. is a leading Chinese biopharmaceutical company that develops, manufactures and commercializes biotherapeutics primarily for the Chinese market. With expertise in all aspects of development and commercialization, Sunway is able to serve as a key partner to leading western bio-pharmaceutical looking to China for clinical trials, manufacturing and/or sales. With a population exceeding 1.3 Billion and rapid growth in personal income, China is still a largely untapped pharmaceutical market. Sunway, through its partnership model and extensive network, is capitalizing on this opportunity. Sunway is currently in the process of closing an investment round to support its rapidly growing operations.
This press release contains forward-looking statements, including
statements about Genzyme's and Sunway's intention to conduct clinical
trials of, and ultimately commercialize HIF-1a in China. These statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those projected in these forward-looking statements.
These risks and uncertainties include, among others: Genzyme's and Sunway's
ability to transf
|SOURCE Genzyme Corp.|
Copyright©2007 PR Newswire.
All rights reserved